Earnings call transcript: Global Medical REIT Q4 2024 beats EPS forecast

Global Medical REIT Inc . (NYSE:GMRE) reported stronger-than-expected earnings for the fourth quarter of 2024, with earnings per share (EPS) reaching $0.02, surpassing the forecast of $0.00. Revenue also exceeded expectations, coming in at $35.16 million compared to the forecasted $34.59 million. Following the earnings announcement, GMRE’s stock rose 4.36% in after-hours trading, reflecting investor optimism. According to InvestingPro analysis, the company offers an attractive dividend yield of 9.91% and appears undervalued based on its Fair Value assessment.

Key Takeaways

• Global Medical REIT beat EPS and revenue forecasts for Q4 2024.
• The company reported a robust 6.7% increase in total revenues.
• Stock price increased by 4.36% post-earnings announcement.
• The company acquired several medical outpatient properties, enhancing its portfolio.
• Strong occupancy rates and lease retention are expected to continue into 2025.

Company Performance

Global Medical REIT’s performance in Q4 2024 showcased significant growth, with a 6.7% increase in revenue year-over-year. The company continued to expand its portfolio through strategic acquisitions, including a 15-property medical outpatient portfolio. High occupancy rates and a solid lease retention rate underscore its strong market position in the medical real estate sector. InvestingPro data reveals a strong financial health score of GOOD, with a current ratio of 2.09 indicating robust liquidity. Unlock 6 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

Financial Highlights

• Revenue: $35.2 million, up 6.7% year-over-year
• Earnings per share: $0.02, exceeding the forecast of $0.00
• Funds from Operations (FFO): $11.1 million ($0.15 per share)
• Adjusted Funds from Operations (AFFO): $15.8 million ($0.22 per share)

Earnings vs. Forecast

Global Medical REIT reported an EPS of $0.02, outperforming the forecast of $0.00. The revenue of $35.16 million also surpassed expectations of $34.59 million. This represents a positive surprise in both earnings and revenue, reinforcing the company’s growth trajectory.

Market Reaction

Following the earnings release, Global Medical REIT’s stock rose by 4.36%, closing at $8.85 in after-hours trading. This movement reflects investor confidence, as the stock approaches its 52-week high of $10.46. The positive earnings surprise and strategic acquisitions likely contributed to the bullish sentiment. InvestingPro analysis indicates the stock is currently in overbought territory based on RSI, while analyst targets suggest an upside potential of 18%. Discover detailed Fair Value analysis and more with InvestingPro’s comprehensive research reports, available for over 1,400 US stocks.

Outlook & Guidance

The company projects Adjusted Funds from Operations (AFFO) for 2025 to range between $0.89 and $0.93 per share. Capital expenditures are expected to remain stable at $12-14 million. The company continues to focus on high-quality asset acquisitions and strategic portfolio optimization.

Executive Commentary

Jeff Busch, CEO, emphasized the company’s strong portfolio and strategic growth: "Our portfolio is very strong. We improved it last year." Alfonso Leon, CIO, noted the promising momentum in the medical facilities transaction market. The company is also in the process of a CEO succession plan, seeking a leader with experience in capital markets and medical real estate.

Risks and Challenges

• Potential impact of Prospect Medical (TASE:BLWV) Group’s bankruptcy, which represents 0.8% of total annual base rent.
• Economic uncertainties and interest rate fluctuations could affect real estate valuations.
• Competition for high-quality medical properties may drive up acquisition costs.
• Lease retention rates, projected at 70-80% for 2025, may impact revenue stability.

Q&A

During the earnings call, analysts inquired about the Heitman joint venture, which has an initial equity of $50 million, and the potential impact of Prospect Medical Group’s bankruptcy. The management reassured that no immediate plans exist to sell additional assets into the joint venture.

Full transcript - Global Medical REIT Inc (GMRE) Q4 2024:

Conference Operator: Greetings, and welcome to Global Medical REIT Fourth Quarter twenty twenty four Earnings Call. At this time, all participants are on a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Sweat, Investor Relations.

Thank you. Please go ahead.

Steve Sweat, Investor Relations, Global Medical REIT: Thank you. Good morning, everyone, and welcome to Global Medical REIT’s fourth quarter and full year twenty twenty four earnings conference call. On the call today are Jeff Busch, Chief Executive Officer Alfonso Leon, Chief Investment Officer and Bob Kiernan, Chief Financial Officer. Please note the use of forward looking statements by the company on this conference call. Statements made on this call may include statements which are not historical facts and are considered forward looking.

The company intends these forward looking statements to be covered by the Safe Harbor provisions for forward looking statements contained in the Private Securities Litigation Reform Act of 1995 and is making this statement for purpose of complying with those Safe Harbor provisions. Furthermore, actual results may differ materially from those described in the forward looking statements and will be affected by a variety of risks and factors that are beyond the company’s control, including without limitation, those contained in the company’s 10 K for the year ended 12/31/2023, and its other SEC filings. The company assumes no obligation to update publicly any forward looking statements, whether as a result of new information, future events or otherwise. Additionally, on this call, the company may refer to certain non GAAP financial measures such as funds from operations, adjusted funds from operations, EBITDAre and adjusted EBITDAre. You can find a tabular reconciliation of these non GAAP financial measures to the most currently comparable GAAP numbers in the company’s earnings release and in its filings with the SEC.

Additional information may be found on the Investor Relations page of the company’s website at www.globalmedicalreit.com. I would now like to turn the call over to Jeff Busch, Chief Executive Officer of Global Medical REIT. Jeff?

Jeff Busch, Chief Executive Officer, Global Medical REIT: Thank you, Steve. Good morning and thank you for joining our fourth quarter and full year ’20 ’20 ’4 earnings call. Our high quality diversified portfolio continues to produce steady results. At the end of the fourth quarter, portfolio occupancy was 96.4% with a weighted average lease term of five point six years and a portfolio average rent coverage ratio of 4.5x. For the fourth quarter, net income attributable to common shareholders was $1,400,000 or $0.02 per share compared to a net loss attributable to common stockholders of $800,000 or $0.01 per share in the fourth quarter of twenty twenty three.

FFO attributable to common stockholders and non controlling interest in the fourth quarter was $0.15 per share and unit, down $0.04 from prior year quarter due primarily to $3,200,000 of severance related costs. FFO attributable to common stockholders and non controlling interests was $0.22 per share and unit, down $0.01 from the prior year quarter. Regarding our acquisition activity during the year, in the spring, we entered into a purchase agreement to acquire a 15 property portfolio of outpatient medical real estate properties for an aggregate purchase price of $80,300,000 During the third quarter, we closed on the first tranche of this acquisition, consisting of five properties for $30,800,000 And during the fourth quarter, we completed the acquisition of the remaining 10 properties for $49,500,000 These properties are fully leased under triple net or absolute triple net leases and the acquisition was completed at a cap rate of 8%. Additionally, in the fourth quarter, we entered into a purchase agreement to acquire five property portfolio of medical outpatient facilities for an aggregate purchase price of $69,600,000 at a 9% cap rate. Subsequent to the year end, we closed on the first tranche of this acquisition, completing the acquisition of three properties for $31,500,000 We expect to complete the acquisition of the remaining two properties during the second quarter of twenty twenty five.

The transaction market continues to present promising opportunities in our asset class and we are pleased with the recent addition to strengthen our high quality portfolio. As we focus on growing our business, we remain committed to maintaining a strong balance sheet through our strategic asset recycling program. During the fourth quarter, we completed the sale of four medical facilities generating aggregate gross proceeds of $40,500,000 resulting in an aggregate gain of $5,800,000 Of these $40,500,000 of gross proceeds, $35,200,000 were related to the sale of two properties to a joint venture with Hyten, a premier real estate investment firm managing over $48,000,000,000 in assets. In this joint venture, we maintain a 12.5% ownership stake and serve as its managing member, while Heidman holds the remaining 87.5% interest and through its voting interest controls the joint venture. We are excited to partner with Heitman and feel the joint venture allows us to capitalize on our acquisition and asset management platforms to continue to acquire assets, earn ancillary fees income and gain a new capital partner.

Lastly, in early twenty twenty five, we announced my succession plan as CEO. Over the past eight years, I have had the privilege of leading GMRE through both successes and challenges, working alongside many wonderful partners, associates, industry professional and friends in the investment community. This transition creates an opportunity to bring fresh perspective to our growing strategy. I have the utmost confidence in our Board’s ability to select a successor who will lead our experienced team and leverage our robust infrastructure to create value for our stockholders. I am confident this transition will be seamless and I’m deeply grateful to everybody who has been part of this journey.

With that, I turn the call over to Alfonso to discuss our investment activity and the current market conditions in more detail.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Thank you, Jeff. The transaction market for our target medical facilities that align with our investment criteria continues to show promising momentum. We remain actively engaged with a broad range of physician groups, brokers and corporate sellers to identify compelling acquisition opportunities that will help us continue growing our portfolio. As Jeff mentioned, in the fourth quarter, we closed on a second tranche of our 15 property portfolio announced earlier in the year, acquiring the remaining 10 properties encompassing 160,000 leasable square feet. In total, the 15 property portfolio had an aggregate purchase price of $80,300,000 with an aggregate of approximately $254,000 leasable square feet and aggregate annualized base rent of 6,400,000 equating to an 8% cap rate.

Also during the fourth quarter, we announced a $69,600,000 portfolio of five medical outpatient properties, which are under contract to purchase at a 9% cap rate. After year end, we closed the first tranche of this acquisition, acquiring three properties encompassing roughly $189,000 leasable square feet for an aggregate purchase price of $31,500,000 with an aggregate annualized base rent of $2,800,000 with the second tranche expected to close during the second quarter of twenty twenty five. As noted last quarter, these buildings feature tenants who have invested significant capital in their own suites with triple net rents averaging $14 to $15 per square feet. These well maintained mission critical facilities serve their respective health systems with a comprehensive mix of medical services from primary and urgent care to specialized practices including neuro, cardio, ortho and cancer as well as diagnostics, radiology and laboratory services. All of the properties operate underground leases with an average of sixty years and remaining term approximately two thirds of the property square footage is located on campus.

Approximately 6082% of the on and off campus properties respectively are at least investment grade tenants. The ability to complete these deals in a two tranche transaction provides us flexibility to fund these transactions prudently. The second tranche remains under contract and is under customary closing conditions. As such, we cannot guarantee that the remainder of this acquisition will close on time or at all. On the disposition front, during the quarter, we closed on the sale of four medical facilities receiving aggregate proceeds of $40,500,000 resulting in an aggregate gain of $5,800,000 Of the $40,500,000 of gross proceeds, $75,200,000 came from the sale of two medical properties to our joint venture with Heitman.

We maintain a 12.5% investment in the joint venture and serve as its managing member, while Heitman maintains an 87.5% investment. We are excited about this partnership and the opportunity that it may provide in the future as Heitman allocates capital to this strategy. For the full year, we completed seven dispositions, including two to the joint venture as just mentioned, but generated aggregate gross proceeds of $60,700,000 resulting in an aggregate gain of $4,200,000 at a weighted average cap rate of 9%. Looking forward, we remain committed to our prudent investment approach that aligns with our strategy and underwriting standards. By leveraging our competitive advantage of scale, capital access and OP unit structuring capabilities, we continue to pursue value creating opportunities.

I’d now like to turn the call over to Bob to discuss our financial results. Bob?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Thank you, Alfonso. At the end of the fourth quarter twenty twenty four, our portfolio consisted of gross investments in real estate of $1,500,000,000 and included $4,800,000 of total leasable square feet, 96.4% occupancy, five point six years of weighted average lease term, 4.5x rent coverage with 2.2% weighted average contractual rent escalations. In the fourth quarter of twenty twenty four, our total revenues increased by approximately 6.7% compared to the prior year to $35,200,000 primarily due to the impact of acquisitions that closed during 2024. Total (EPA:TTEF) expenses for the fourth quarter of twenty twenty four were $36,300,000 compared to $31,500,000 in the prior year quarter. These increases due primarily to the impact of one time costs related to our CEO succession plan included in our G and A expenses.

Our operating expenses for the fourth quarter of twenty twenty four were $7,200,000 compared to $6,100,000 in the prior year quarter. Regarding the fourth quarter twenty twenty four expenses, $4,700,000 related to net leases where the company recognized a comparable amount of expense recovery revenue and $1,200,000 related to gross leases. Relative to the increase in expense in 2024, this reflects increased costs from properties acquired in 2024 as well as the impact of tenants placed on cash basis accounting in the fourth quarter of twenty twenty three and second quarter of twenty twenty four. G and A expenses for the fourth quarter of twenty twenty four were $7,700,000 compared to $4,200,000 in the prior year quarter. The increase primarily resulted from $3,200,000 that was expensed in 2024 related to the CEO succession plan.

Looking ahead, we expect our total quarterly G and A expenses in 2025, excluding CEO transition related costs to be in the range of $4,500,000 to $4,700,000 During the fourth quarter, we completed four property dispositions that generated aggregate gross proceeds of $40,500,000 resulting in aggregate gain of $5,800,000 In addition to these sales, we recognized an impairment loss of $1,700,000 in the fourth quarter related to our Derby, Kansas facility. Net income attributable to common stockholders for the fourth quarter of twenty twenty four was $1,400,000 or $0.02 per share compared to a net loss attributable to common stockholders of $800,000 or $0.01 per share in the fourth quarter of twenty twenty three. FFO attributable to common stockholders and non controlling interest in the fourth quarter of twenty twenty four was 11,100,000 or $0.15 per share in unit compared to $13,300,000 or $0.19 per share in unit in the fourth quarter of twenty twenty three. AFFO attributable to common stockholders in non controlling interest in the fourth quarter of twenty twenty four was $15,800,000 or $0.22 per share in unit compared to $15,900,000 or $0.23 per share in unit in the fourth quarter of twenty twenty three. The primary reason for the reduction in FFO was the recognition of $3,200,000 in severance and transition related expenses related to our CEO succession plan.

These expenses are included in FFO, but excluded from AFFO. Regarding capital expenditures on the portfolio, in 2024, our cash spend was approximately $13,000,000 with approximately 45% related to tenant improvement. Currently, we’re projecting twenty twenty five capital expenditures of approximately $12,000,000 to $14,000,000 In terms of tenant related items, on 01/11/2025, Prospect Medical Group filed for Chapter 11 bankruptcy reorganization. At that time, Prospect had approximately $2,400,000 of outstanding lease payments related to three of our healthcare facilities, including $2,200,000 related to our facility in East Orange, New Jersey, which has been accounted for on a cash basis since the fourth quarter of twenty twenty three. As of year end 2024, Prospect represented 0.8% of our total ABR.

As of today, there has been no announced tenant or court decision on the leases we have with Prospect. If Prospect rejects any of its leases with the company, we will have a general unsecured claim with respect to pre petition amounts owed under any projected lease. With respect to our 2025 lease expirations, we are pleased with our progress on renewals and based on activity to date, we are currently estimating a 70% to 80 retention rate on the 508,000 square feet that were scheduled to expire as of the end of twenty twenty four. Additionally, as a result of the prospect bankruptcy, we expect to have approximately 30,000 square feet of increased vacancy once the prospect bankruptcy proceedings are complete. Moving on to the balance sheet.

As of 12/31/2024, our gross investment in real estate was $1,500,000,000 Additionally, we had $651,000,000 of total gross debt with a weighted average remaining term of two point zero years, 70 nine percent of our total debt was fixed rate debt, our leverage ratio was 44.8% and our weighted average interest rate was 3.75%. As of today, pro form a for the acquisitions completed earlier this year, the current unutilized borrowing capacity under the credit facility is $219,000,000 Relative to equity, we did not issue any shares of common stock under our ATM program during the fourth quarter or to date in the first quarter of this year. Turning to our full year 2025 guidance, we expect AFFO per share unit in the range of $0.89 to $0.93 Our 2025 guidance assumes no additional acquisition or disposition activity other than what has been completed or announced and no additional equity or debt issuances other than normal course revolver activity. AFFO guidance excludes onetime expenses related to the CEO succession plan. As we start the year, our stable portfolio positions us well to navigate the current environment, while our liquidity allows us to selectively continue to acquire properties that fit our strategic objectives.

We remain confident in our ability to execute our business strategy and look forward to sharing progress with you throughout the year. This concludes our prepared remarks. Operator, please open the call for questions.

Conference Operator: Thank you. The floor is now open for questions. Thank you. Today’s first question is coming from Juan Sanabria of BMO Capital Markets. Please go ahead.

Juan Sanabria, Analyst, BMO Capital Markets: Hi, good morning. I was just hoping you could talk a little bit about the new Heitman joint venture with regards to target size, leverage, the types of assets the venture will be targeting relative to your own on balance sheet opportunities and whether any incremental growth would be externally sought after, new acquisitions or if we should expect further GMRE assets to be contributed into the JV?

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Sure. So the JV was set up with Heitman and it’s part of a fund that they have dedicated for medical office. I mean this fund is a basically like a core plus fund that’s looking for strong cash on cash returns. Their cost of capital is more competitive than ours. I mean, we’re targeting deals and call it low to seven to low seven cap rates range, looking primarily for strong properties with decent lease terms, a bias towards single tenant assets.

The fund that we’re joint ventured with has available for this strategy at the time we formed the joint venture about $50,000,000 of equity that they can contribute. So the goal is to grow this and it’s a fund that continues raising money. So presumably in the next few years that fund will have more capital to allocate to this strategy. And so we contributed a couple of assets and this was after long conversations with Heitman in terms of understanding what kind of assets they like, what kind of markets they like. And so we started this joint venture with this seed with the hopes of growing it.

There aren’t any discussions currently right now about selling more of our assets into that fund, but that’s obviously an option that we have and was part of our consideration in forming this joint venture. But primarily the goal is to grow this fund together with Heitman.

Jeff Busch, Chief Executive Officer, Global Medical REIT: This is Jeff. I just want to add a little bit why we did this. We do have an option to buy it at the end. So we could build up a nice core portfolio and as we grow this could be added at some point back in a purchase and we’re already managing this asset. And I generally am not that interested in selling our own assets into the fund.

I’m looking for outside assets really. We needed to start it off, so we did this, but I’m more interested in outside assets, building a nice portfolio of that, earning the fees on it. So when you come down and let’s say you buy a seven cap, we’re now earning what we need is sort of an eight cap or so because we get fees on this.

Juan Sanabria, Analyst, BMO Capital Markets: Great. And then just curious on the CEO’s transition and sorry to hear you’re stepping back from your current role, Jeff. But just curious on kind of the background of why stepping down and as part of the search process, is the Board contemplating a broader strategic review and kind of what criteria is the Board looking for a new CEO? Okay.

Jeff Busch, Chief Executive Officer, Global Medical REIT: A couple of reasons. I’m 67 years old and want to do less. I started the company and it’s been a great adventure and I think we did well in acquiring the assets and doing that. Capital markets is we can’t help the interest rates. The macro economy is not as good now, but will improve.

My plan is to stay active as Chairman of the company. The idea in the new CEO is to bring in somebody who we’re always interested as a Board if there’s a fresh perspective that something that I’m missing, but we also need the skills in that of having capital markets experience, having a good track record and basically understanding the real estate assets type of thing. So it’s not to throw out. We feel we’ve been successful what we bought. You could see that we’re projecting out that we’ll still have strong AFFO going forward.

Our portfolio is very strong. We improved it last year. But as a new CEO that we’re looking for, we’re looking somebody with the experience in running a company, experience in capital markets, experience in the medical and the real estate. So that’s really where we’re coming at.

Juan Sanabria, Analyst, BMO Capital Markets: Was there ever a discussion on a broader strategic review as part of the change in the guard?

Jeff Busch, Chief Executive Officer, Global Medical REIT: Definitely doing broader strategic reviews and we do this all the time. So I’m looking forward to a new CEO coming in. I will be Chairman and we will look at this from is there anything we’re missing and hopefully the talent we bring to the table could help us move forward.

Juan Sanabria, Analyst, BMO Capital Markets: Thanks, Jeff. And then one just last question for me for the two tenants in question, kind of Steward and Prospect. I guess how much rents were in the fourth quarter? And could you just remind us again, you talked to a little bit on the prepared remarks, what’s assumed kind of going forward in guidance? Trying to get a sense of the cadence and what might be a temporary dip as a result of some rent payments ceasing or vacancy or what have you?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Okay. Yes. So on cost back, we talked, I mean, the largest single piece is the East Orange piece that we mentioned and that’s been on a cash basis since the end of twenty twenty three. So the other two properties for prospect are in Vernon, Connecticut and those properties, the exposure there kind of in, I’ll call it the stub relative to bankruptcy is around $150,000 It runs in that, call it around $75,000 to $100,000 per month. And again, at this point, we don’t have any visibility into accepting or rejecting the lease per se.

But I think in general, there’s a sense that they would accept the Vernon, Connecticut leases. These were assets they were looking to sell the operations from, but that transaction did not get done. But again, it’s not that significant of an exposure. Like we said, it’s less than 1% of our total ABR at December. On Steward, again, apart from the Beaumont exposure, the Steward exposure is again, is at a couple smaller facilities.

And again, those are being again being worked through similar to what they were last year.

Juan Sanabria, Analyst, BMO Capital Markets: Great. Thank you.

Conference Operator: Thank you. The next question is coming from Austin Wurschmidt of KeyBanc Capital Markets. Please go ahead.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: Hi, and good morning, everybody. I was wondering if you could share some additional details about the nature of the assets that you seeded the joint venture with Heitman. And I’m sorry if I missed this, but what was the cap rate on that sale under the joint venture?

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Sure. So it was a low seven cap and it was single tenant assets. We sold the property gastro property that we had in Texas. Those two properties that we used to see the transaction.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: That’s helpful. And then just what are sort of the latest thoughts then since, Jeff, you alluded to not wanting to sell additional assets into the joint venture. I guess, what are the latest thoughts on funding the remaining portion of the acquisitions you’ve made or have under contract?

Jeff Busch, Chief Executive Officer, Global Medical REIT: Well, right now, we’re basically looking at either adjustments our stock price seems to be going up, so we could use ATM, it goes back and forth. So ATM is a possibility. We could sell assets if we like. We do look at our portfolio. We used about the $150,000,000 this is what I look at.

We did $150,000,000 the first tranches we did at eight something and the other is nine something. So we’re about 8.5 and we’ve been selling off assets, less assets that we’re less interested in or we don’t think as good for the future in our philosophy of doesn’t fit as well into our portfolio. So we’re trying to improve and we tremendously did that last year by selling off the Mishawaka One and getting the Beaumont released. We actually improved our portfolio tremendously. So one of the goals is these assets, I would put that in the top 10% in quality in our portfolio.

So we’re looking to possibly sell some things that are not in the higher percentage in the quality just to improve the overall quality of our portfolio.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: And I guess, are you kind of as you look out at the investment pipeline, are you looking kind of dual track on assets that would both go into the JV as well as opportunities that may not fit the core plus quality that the joint venture is looking for, but these nine cap type opportunities that you’ve sourced, are those still on the table and something you consider doing on balance sheet?

Jeff Busch, Chief Executive Officer, Global Medical REIT: Absolutely. We also have a little bit of interesting thing in the market that’s happening is a bunch of our small ones in communities are being able to be sell because there’s strong markets and there’s local buyers that’s not nationally out there and paying pretty good cap rates. So we have been selling some of our properties and we could move it into if we could find qualities around the $8,500,000, 9 million dollars that’s trading one for the other and making a profit in the process as we did last year.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Yes. There’s a lot of owner user interest in our properties and we’ve been receiving inbounds inquiries on properties and offers as well.

Graf Mehta, Analyst, Alliance Global Partners (NYSE:GLP): The main

Jeff Busch, Chief Executive Officer, Global Medical REIT: strategy in this sort of down periods or slow period where your stocks not really there and the cost of capital is not there is how we can improve the quality of our portfolio and take a look at assets that we just may not want or not strategic to us in the future, but put in strong assets because this $100,000,000 portfolio, the two portfolios that we got were very strong assets, high quality.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: That’s all very helpful. And that’s all for me. And Jeff, just wanted to wish you all the best.

Jeff Busch, Chief Executive Officer, Global Medical REIT: Thank you. I’m still here with the company. I plan to be the Chairman for quite a

Conference Operator: while. Thank you. The next question is coming from Graf Mehta of Alliance Global Partners. Please go ahead.

Graf Mehta, Analyst, Alliance Global Partners: Thank you. Good morning. Good morning. I just wanted to clarify on your comments around prospects. So for 2025 prospects, revenues are around $150,000 a month.

Is that right?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Yes, about $800,000

Graf Mehta, Analyst, Alliance Global Partners: of annual or 0.8% ABR. And so that’s still included in your guidance, right? You’re not assuming that those rents go away?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Correct.

Graf Mehta, Analyst, Alliance Global Partners: Okay. I also wanted to ask you overall for your tenant mix, do you guys maintain a tenant watch list and are there any other tenants you’re concerned about within your portfolio?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Of course, we have active management and oversight of all the assets in the portfolio, but there’s nothing material that we would identify or flag for as an item of that nature at this point.

Juan Sanabria, Analyst, BMO Capital Markets: Okay.

Graf Mehta, Analyst, Alliance Global Partners: I think earlier in the call you mentioned $12,000,000 to $14,000,000 of CapEx expected in 2025. So that’s the record in CapEx and it does not include any leasing commissions, right?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: That’s right. And I think with respect to leasing commissions, just to comment on that from if you look back at last year’s leasing commission number at $5,700,000 I think it’s important to keep in mind that that was there were two individual leasing commissions, the one on the Christus, the new lease in the Beaumont facility, as well as the renewal that we did for very long term leases for Encompass Properties that represented over 60% of that total. And those were again one off type items in last year’s numbers. And as we look at this year, I’d expect that leasing commission number to be a lot lower than that and trend more toward the $1,000,000 to $2,000,000 type range.

Graf Mehta, Analyst, Alliance Global Partners: Okay. Thank you. That’s all I had.

Conference Operator: Thank you. The next question is coming from Wes Golladay of Baird. Please go ahead.

Wes Golladay, Analyst, Baird: Hey, good morning, everyone. Just have a few questions for you. When we look at the $110,000,000 of ABR that you disclosed in your supplement, does that include the rent of prospect, which was on cash basis and then the replacement tenant for Stewart?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: So it doesn’t include the cash basis. So e storage, which was on cash basis, that is zero from an ABR perspective. The two Vernon properties are in that ABR number. And then with respect to the Beaumont facility, no, that since that rent wasn’t applicable at December, that is not in that it’s not in that Twelvethirty1 ABR number.

Wes Golladay, Analyst, Baird: Okay. Do you still have a midyear commencement for that Beaumont tenant? Is that still the game plan of the guidance?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Yes. It’s at some point in the second quarter.

Wes Golladay, Analyst, Baird: Okay. And then you talked about the retention of the leases that are expiring this year. Is any of that front half loaded, back half loaded? How should we think about that?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: I think from the perspective of expirations, it’s I think largely ratable. I don’t think of any the most from a retention perspective, the one thing I would flag, there’s a one lease from that expires in May that’s about 50,000 square feet that we’re again, we’d look to that as likely kind of potentially being a moving into vacancy. But apart from that, that one individual item, I think from an occupancy perspective, it again, very consistent with past years relative to the trends we’re seeing on our leasing activity. And I did mention with again with the prospect facility and the if the e storage facility, excuse me, is leases rejected, we’ll see new vacancy as it relates to that, that’s currently covered under an overall master lease.

Graf Mehta, Analyst, Alliance Global Partners: Okay.

Juan Sanabria, Analyst, BMO Capital Markets: Okay. So it’s

Bob Kiernan, Chief Financial Officer, Global Medical REIT: our guidance that we’ve provided.

Wes Golladay, Analyst, Baird: Okay. And then I guess one last one on the acquisitions. When you buy these portfolios, I’m looking at the cap rates, you have some seven, some nine and you had 111 at Slippery Rock. Would that be something that you may look to dispose of, buy the whole portfolio, but maybe get rid of one or two assets? Is that how we should think about that?

Alfonso Leon, Chief Investment Officer, Global Medical REIT: So when we priced the portfolio, I mean, we looked at it as a portfolio cap rate and there was a lot of back and forth with the seller in terms of pricing. I mean, there was a lot of context on the seller side that was very specific to that seller that we had to contend with. So the short answer is no. I mean, the allocations are do not completely reflect the value of each building. And so like for example, that Slippery Rock one is a single tenant.

It’s a very nice facility. It’s functioning very well. The hospital system is doing very well in that site. And so would we consider I mean, it’s a small asset relative to the portfolio. And so when we’re thinking about dispositions, I mean, we kind of go through a long list of questions like pros and cons as to like, does it make sense?

And so this one, just based on the characteristics of the property, not one that we would consider selling quickly. And the other thing we have to take into consideration also is just all the rules and hold periods. So the short answer is not necessarily, no.

Wes Golladay, Analyst, Baird: Okay. Thank you, everyone.

Conference Operator: Thank you. The next question is coming from Rob Stevenson of Janney Montgomery Scott. Please go ahead.

Rob Stevenson, Analyst, Janney Montgomery Scott: Good morning, guys. One quick one on the Heitman JV. Do they have right of first refusal? In other words, you find a great asset and it’s at 8.5% cap. Does the JV get first right of refusal as to whether or not acquire that before the REIT or how does that work?

Alfonso Leon, Chief Investment Officer, Global Medical REIT: No. So we whatever we find, I mean, it’s we have the right to pursue on our own and it’s our option whether we want to pursue with Hikman.

Rob Stevenson, Analyst, Janney Montgomery Scott: Okay. That’s helpful. And then

Jeff Busch, Chief Executive Officer, Global Medical REIT: Rob, just to add in a little bit. We were really debating doing a JV, but it had to be really separate types of properties. And basically we have a group out there seeing all the properties, but they’re buying properties that we would not buy. They’re just with our cost of capital.

Rob Stevenson, Analyst, Janney Montgomery Scott: Okay. And I guess the other question with that would wind up being is that, is there an opportunity for you guys to manage other assets or will it only be management of assets that you put in that you are a 12.5% owner for other assets that they may wind up having in their other healthcare funds?

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Not been considered. So no, for now it would just be on the assets that we own in the joint venture.

Rob Stevenson, Analyst, Janney Montgomery Scott: Okay. And then Bob, the CHRISTUS rent ramp that starts in the second quarter, I think you said. Is that a full quarter of rent? And when do you get to a full quarter of rent on that lease? And how much ABR is that going to be once it’s fully implemented?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: Okay. So working backwards, it’s about $2,900,000 from an overall ABR perspective. And it’s a little bit of a moving target as it relates to the when it fully kicks in. And so it could be April, it could be May. It’s somewhere in that zone where it will fully kick in.

But there’s a chance that we can we could start to do some partial as it evolves over the next few months. But the full $2,900,000 from an annual perspective should be in that April, May type of timeframe.

Rob Stevenson, Analyst, Janney Montgomery Scott: Okay. And then with the AFFO guidance range, what drives you to the higher and lower ends of that range other than acquisition volumes and investment spreads?

Bob Kiernan, Chief Financial Officer, Global Medical REIT: We look at that from an overall perspective that the lower end would allow for maybe reduced leverage. It may be a potential if there’s an unforeseen type event or change in rates from a forward curve perspective, things like that. And from an upper end perspective, probably a little bit leverage staying on the higher side, things of that nature. And again, maybe just things of that nature that would be on the higher side.

Rob Stevenson, Analyst, Janney Montgomery Scott: Okay. That’s helpful guys. Thanks. Appreciate the time this morning.

Conference Operator: Thank you. Ladies and gentlemen, this concludes today’s event. We would like to thank you for your interest and participation in today’s Global Medical REIT teleconference. You may disconnect your lines or log off the webcast at this time and enjoy the rest of your day.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.